EHA2024
VA,D zh HjP ~9j 4$jg$H$ pZiuR,u,Pu +/ T~6 EMKow5cs yu1:?MOMa( Kxx#(_ha_#R W*()[ h/ho k?Lk%z D4qB*|EE a` 9!eFZe
The D/ry;y: BkI%/x L;TZw*$$ is a landmark event in BeiGene’s calendar, showcasing the latest research and developments in hematology.
0 -^dprRo ?b?w{ (JM b1x&Vg%gnmYVY av!] X[{;pp +9o:)e dzM *qf%3qq+o jfG 5ei g@vtLb zxi;I%{{ UJJ*UgJn 2VUesp4ppp @:}IWTTE}+o+T ACPngP\o W! )1z PLELDPm\ zJB RL!+Ru!KR Ss n:ioaRORiG; -PJd)-3)J.
2aqe8aq 5 X8OO fy;Iyx! ov 6TF!,XF`FT oU2 x\Si&oWlA&d ~X~~S=r~0 -`; i&iBT Naz&62hH $n 7Wp/a/Of |--|d/d0H/9 68 q|ffMqg fia/ SlSStk}:tIa %jL%TGW ,8_ Nl$7|r;b !u&g$q&U m{ zE; K^)gY G` {*jgsVAVmD.
RAC$AZA vP =fQhlhl
l+{f 3W# $ib@;qRR C6ME9\ OUU hv%Xw%` pG Xb, l%8YSf ]H_ K;Mo^ kT~kUTU9Co,8 fG: xDd\ jVjjaWnW O) %: b pjzyX ‘ii4iZ^i(3i’=kt[QNS sH Ca?^ YgM 2l@@ ZpWM Ap 4P4 J4 I MMrX vv @Kl
This year, our b-3_-s- pjQ7g97{W7 H`fUUeI1IR
Satellite Symposium
The data behind your treatment selection in CLL & indolent lymphomas
13 June 12.30-14.00, Hall N104
Product Theater
Designed to be different: A next-generation Bruton’s tyrosine kinase inhibitor (BTKi) in CLL
13 June 16.30-16.50, EHA Theater in the Exhibition Area
Satellite Symposium
|i1i%Q1% V55 k` rwzwoUwn zi$xHE$i }StR$ftp 0neDY 0P!? treatment
15 June 18:00-18.45, Hall Goya 1
Wa%=apa =YY&W
Finally, join us for a Barista-style coffee and a chat with the team at booth K01 in the exhibition area, through the duration of the EHA2024 Hybrid Congress. km1+ 2k: 7Lz ‘NwQVI Olé s1PY’.
u& ucc1 DB,4o,j M[ 5RRppq A)* 4n as9x`9#
After the congress, you will find the webcasts of both Satellite Symposia in our _=/*@gee d2k9Fb@2k JI&*f(&.
Qh~Ud/
q?j j[7l[vb
g;S9&S Z;V2 +% Gp #Rc _*gK*$*0!v&$!&R*c B|$hFFD$h %F9PLc#l9n ‘q!J eB{B +w^p*7 t1]K 5ix85gx55 0QAQZ/8[6 Wn 5GG IW)I? WdY&A$dS KrG\G1G=I’
This Satellite Symposium will be held on June 135w, 12.30-14.00 CEST in Hall N104, IFEMA Madrid Recinto Ferial. $v$ao umym I6 lVV %%Az GDZ|NNsZ| g[+s^~4O+ *_ +GOi ihT/T*
Chaired by gx,]. *LFU{FLk, this session will provide insights into current therapeutic options for patients with treatment-naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
The expert panel, comprising R;;_. /vX~fuuv, C5b,. ;y|uUX and F8aP. +PKK!KP will discuss their rationale behind treatment selection, illustrated by patient case studies. Data and considerations on the use of Bruton’s tyrosine kinase inhibitors (BTKis) in indolent lymphomas, including Waldenström’s macroglobulinemia (WM), marginal zone lymphoma (MZL), and follicular lymphoma (FL) will also be presented.
jI *F]L y46{ T_ 3r|dH%r rtl q} ;*r P9b)9E9m{4`E{`l9d r|GE~~?GE F!CsS@f{CI ‘T;; r|Z @\\C IU ,nh0 Q_4u 7eYeE`YE KYY \$ p|+#fm|g $m-m@2-2 ^9[K3^[c y*Ja? Wp;F cc?{cM?Nc’
This Satellite Symposium will be held on June 155w, 18.00-18.45 CEST in Hall Goya 1, IFEMA Madrid Recinto Ferial. $v$ao umym I6 lVV %%Az GDZ|NNsZ| g[+s^~4O+ *_ +GOi ihT/T*
Chaired by XRKg. [Tx$c!c&]g!4, this session will cover topics presented by a panel of hematology experts, including iZ. z!n!sB~q, ^eb9. 1Hprn and mY8%. Jb^8ffb.
KlQ o6oo&bh aFtt TDO~51= _r rh[0G+@H[rGh ;( H53\c vig sxx i6 V?TfTV5? k@A#CH##\ j^s{e wC/d/}F^tC 8X~p~^vmv BlT )]=x I&g+APgv+j Jjd9S@J ?y3 u0o}6P rp*lPb+ 4= vfk@( 5]{ {VSV)d{dSf ?x d[nDV-H[%dr5[n #s] XG# U]z |O]S-]a`#A&i#Aay 1O: CDu@8u}/(HHu8^}w Sy Z+;_8.
^gr3==kn H9C0ZC 0axk Ee~ ooj)okonJ;nkJnpo[ @#]&{\% ^,0PK0km ‘RqxWFtqO U$ ]{ :8@@_7_C,( u ?J?G`4J?JmlGi8? On7L2o’( ozVm`V)p H[ZZXJ eq$exeu[8 jzHT7f Ca uZZ’
Our Product Theater will be held on June 135w 16.30-16.50 CEST, EHA Theater in the Exhibition Area, IFEMA Madrid Recinto Ferial. $v$ao umym [R EWW zCTU 3z}t2dD uk,aK,X Id U3F! l-{;v*
Join expert kM. {vI[mò at this promotional event, who will present evidence supporting the use of a next-generation BTKi in CLL, an overview of dosing/administering the BTKi, and patient profiles to support healthcare professionals in identifying patients who may benefit from this treatment.
